title: [The effect of chenodesoxycholic acid on cholesterol gallstones (author's transl)].
abstract: 30 patients with radiolucent gallstones and 2 patients with radioopaque stones recieved chenodesoxycholic acid (CDC). In 12 patients stones were dissolved completely by CDC therapy, in 6 of the patients the size of the stones decreased by 40-70%. Only 1 patient developed severe diarrhea, so therapy had to be stopped. In 5 patients there was a slight and transient increase in SGOT and SGPT, in 2 other patient gammaGT increased; value normalized while treatment was continued. In 23 cases liver biopsies were done before and during treatment: no histological changes could be found in the specimens. 5 of the patients, whose gallstones had been dissolved, received 500 mg CDC/day thereafter, another 5 patients received 500 mg/d every other day. No recurrence of lithiasis was observed in either group. One patient on 500 mg CDC twice a week developed lithiasis after 6 months, another one stopped treatment completely and gallbladder stones reappeared after 8 months. The patients with radioopaque stones did not show any changes during treatment.
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002635:Chenodeoxycholic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002769:Cholelithiasis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011859:Radiography; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D002635:Chenodeoxycholic Acid; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
vernacular_title: Wirkung der Chenodesoxycholsäure auf Cholesteringallensteine.